113 related articles for article (PubMed ID: 8020082)
1. Is pre-treatment testosterone a prognostic factor in prostate cancer?
Akumabor PN
Cent Afr J Med; 1993 Aug; 39(8):170-2. PubMed ID: 8020082
[TBL] [Abstract][Full Text] [Related]
2. Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer.
Zhang XZ; Donovan MP; Williams BT; Mohler JL
Urology; 1996 Mar; 47(3):402-4. PubMed ID: 8633409
[TBL] [Abstract][Full Text] [Related]
3. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy.
Yamamoto S; Yonese J; Kawakami S; Ohkubo Y; Tatokoro M; Komai Y; Takeshita H; Ishikawa Y; Fukui I
Eur Urol; 2007 Sep; 52(3):696-701. PubMed ID: 17412490
[TBL] [Abstract][Full Text] [Related]
4. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
5. Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma.
Iversen P; Rasmussen F; Christensen IJ
Scand J Urol Nephrol Suppl; 1994; 157():41-7. PubMed ID: 7939452
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of advanced prostatic carcinoma.
Lukkarinen O; Lehikoinen K
Ann Chir Gynaecol Suppl; 1993; 206():9-13. PubMed ID: 8291878
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.
Massengill JC; Sun L; Moul JW; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Donahue T
J Urol; 2003 May; 169(5):1670-5. PubMed ID: 12686805
[TBL] [Abstract][Full Text] [Related]
8. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
Grande M; Carlström K; Rozell BL; Stege R; Pousette A
Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899
[TBL] [Abstract][Full Text] [Related]
10. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
Shimbo M; Suzuki H; Kamiya N; Imamoto T; Komiya A; Ueda T; Watanabe M; Shiraishi T; Ichikawa T
Eur Urol; 2005 Apr; 47(4):557-63. PubMed ID: 15774258
[TBL] [Abstract][Full Text] [Related]
11. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
12. [Time-course of plasma testosterone in patients with prostate cancer treated by endocrine therapy].
Peyromaure M; Rebillard X; Ruffion A; Salomon L; Villers A; Soulie M;
Prog Urol; 2008 Jan; 18(1):2-8. PubMed ID: 18342148
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1143-9. PubMed ID: 19117691
[TBL] [Abstract][Full Text] [Related]
14. Subcapsular orchidectomy in the management of prostatic carcinoma in Nigerians.
Magoha GA
East Afr Med J; 1989 Jun; 66(6):400-3. PubMed ID: 2791945
[TBL] [Abstract][Full Text] [Related]
15. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
[TBL] [Abstract][Full Text] [Related]
16. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
D'Amico AV; Renshaw AA; Loffredo B; Chen MH
Cancer; 2007 Oct; 110(8):1723-8. PubMed ID: 17828774
[TBL] [Abstract][Full Text] [Related]
17. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A
Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749
[TBL] [Abstract][Full Text] [Related]
18. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.
Bastide C; Kuefer R; Loeffler M; de Petriconi R; Gschwend J; Hautmann R
Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy.
Imamoto T; Suzuki H; Fukasawa S; Shimbo M; Inahara M; Komiya A; Ueda T; Shiraishi T; Ichikawa T
Eur Urol; 2005 Mar; 47(3):308-12. PubMed ID: 15716191
[TBL] [Abstract][Full Text] [Related]
20. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer.
Mehra N; Penning M; Maas J; van Daal N; Giles RH; Voest EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):421-6. PubMed ID: 17255261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
